JGC
APLS

J. Goldman & Co’s Apellis Pharmaceuticals APLS Stock Holding History

J. Goldman & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-149,000
Closed -$3.74M – 660
2025
Q4 		$3.74M Sell
149,000
-157,900
-51% -$3.7M 0.1% 235
2025
Q3 		$6.95M Buy
306,900
+143,400
+88% +$3.34M 0.17% 159
2025
Q2 		$2.83M Buy
+163,500
New +$3.03M 0.07% 252
2023
Q4 		– Sell
-67,500
Closed -$2.57M – 339
2023
Q3 		$2.57M Buy
+67,500
New +$2.97M 0.09% 186

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

J. Goldman & Co's APLS Position: Q1 2026 in Review

J. Goldman & Co sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 285,992 shares — an estimated $7.18M sold.

J. Goldman & Co first reported a position in APLS in Q4 2021 and held it in 7 quarters. The position peaked at $7.18M in Q4 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • J. Goldman & Co reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 285,992 Apellis Pharmaceuticals shares in Q1 2026, an estimated $7.18M.
  • J. Goldman & Co first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • J. Goldman & Co's Apellis Pharmaceuticals position peaked at $7.18M in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.